Peginterferons in Hepatitis C Virus: Virological, Pharmacokinetic, and Clinical Implications

Emmet B. Keeffe

doi:10.1055/s-2003-41395

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2003; 23: 001-002
DOI: 10.1055/s-2003-41395

INTRODUCTION

Peginterferons in Hepatitis C Virus: Virological, Pharmacokinetic, and Clinical Implications

Emmet B. Keeffe

Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California

Abstract

Full Text

References

REFERENCES

1 Detre K, Belle S, Lombardero M. Liver transplantation for chronic viral hepatitis. Viral Hepatitis Rev . 1996; 2 219-228
2 Alter M J, Kruszon-Moran D, Nainan O V. et al . The prevalence of hepatitis C virus in the United Status, 1988 through 1994. N Engl J Med . 1999; 341 556-562
3 Seeff L B. Natural history of chronic hepatitis C. Heptology . 2002; 36 S35-S46
4 Charlton M. Hepatitis C infection in liver transplantation. Am J Transplant . 2001; 1 197-203
5 Blatt L M, Mutchnick M G, Tong M J. et al . Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat . 2000; 3 196-202
6 Reddy K R, Hoofnagle J H, Tong M J. et al . Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology . 1999; 30 787-793
7 Sherman K E, Rouster S D, Chung R T. et al . Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trial Group. Clin Infec Dis . 2002; 34 831-837
8 Sulkowski M S, Thomas D L. Hepatitis C in the HIV-infected person. Ann Intern Med . 2003; 138 197-207
9 Lam N P, DeGuzman L J, Pitrak D. et al . Clinical and histologic predictors of response to interferon-alpha in patients with chronic hepatitis C viral infection. Dig Dis Sci . 1994; 39 2660-2664
10 Lam N P, Pitrak D, Speralakis R. et al . Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Dig Dis Sci . 1997; 42 178-185
11 Fried M W, Shiffman M L, Reddy K R. et al . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med . 2002; 347 975-982
12 Neumann A U, Lam N P, Dahari H. et al . Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science . 1998; 282 103-107
13 Rosen H R, Ribeiro R R, Weinberger L. et al . Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. J Hepatol . 2002; 37 124-130
14 Manns M P, McHutchison J G, Gordon S C. et al . Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet . 2001; 358 958-965